Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors

Abroad (travel likely)RecruitingPHASE1

Conditions

Solid Tumor, Adult · Bladder Cancer · Urothelial Carcinoma · Triple-negative Breast Cancer · Lung Cancer · Colorectal Cancer · Gastric Cancer · Ovarian Cancer · Pancreatic Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Melbourne Theranostic Innovation Centre (MTIC), North Melbourne, Victoria, Australia
Contact: Study coordinator (Referral Coordinator) · info@mtic.net.au · 03 9454 5800

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

Solid Tumor, Adult · Bladder Cancer · Urothelial Carcinoma

Abroad (travel likely)RecruitingPHASE1

North Melbourne, Australia

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Solid Tumor, Adult · Colorectal Cancer · Non Small Cell Lung Cancer

Abroad (travel likely)Recruiting

Gilbert, United States · Phoenix, United States

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Diffuse Astrocytoma, IDH-Mutant · Glioblastoma, IDH-wildtype · Brain Metastases, Adult

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beverly Hills, United States · Glendale, United States

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Advanced Solid Tumors With KRAS G12C Mutations · Solid Tumor, Adult · Unresectable Solid Tumor

Abroad (travel likely)RecruitingPHASE1, PHASE2

La Jolla, United States · Orange, United States